Endpoints News

Attovia files to go public		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

M T Wed Th F

15 July, 2026

The most differentiated science stays out of public view. This September, the Endpoints newsroom reveals the 11 private companies worth watching, live at the State Room in Boston. See the list first, reserve your spot and save with the early bird rate.

SPOTLIGHT

Live today at 12 p.m. ET: What’s making biotech IPOs work again?

news

Veradermics declares first efficacy win in women for hair loss drug

I&I startup Attovia files to go public as biotech listings momentum builds

Celcuity wins approval for breast cancer drug Revtorpyk

Jul 30

1:00 pm ET

Accelerating Phase 1 decisions with liquid biopsy: From early signals to actionable insights

sponsored by IBM

A year into the tariff era, the biopharma industry has stopped bracing for impact — however manufacturing and supply chain leaders are still rewriting their plans on the fly. We’re bringing together the experts tracking what R&D logistics looks like today. Join us — find out what’s next.

ENDPOINTS PHARMA

What’s the status of House lawmakers’ bill on China biotech restrictions?

Questions linger over Biogen's tau drug for Alzheimer's, as low dose reports better results

AstraZeneca to take rights to Dizal's lung cancer pill for $600M upfront

in case you missed it

After $4.7B sale to Novo Nordisk, former Akero team announces new I&I company with China drug

Chai Discovery gets $400M, tripling valuation from seven months ago

Draig nets $65M to advance depression drug aimed at rebuilding synapses

Exclusive: Genetic medicine startup launches to speed programs that stalled at Editas, Biogen

News Briefing

Erasca's $550M offering; Summit sells an antibiotic

In latest deal, Innovent seeds Spero's future beyond GSK-owned antibiotic

Roche to test brainshuttle therapy in bid to prevent Alzheimer’s

The race to commercialize the world’s most powerful psychedelic

Attovia joins Scribe and Apnimed in the queue of biotechs looking to go public in the coming weeks. What's feeding the IPO momentum and how long will it last? Later today, we'll be asking these questions to chief execs from Parabilis and Kailera, which pulled off the two biggest biotech IPOs of all time. Tune in here at 12 p.m. ET.